Turn Therapeutics Inc.

GRI Bio, Inc.

Supernus Pharmaceuticals, Inc.

Eikon Therapeutics, Inc.

Candel Therapeutics, Inc.

Compass Therapeutics, Inc.

Lexicon Pharmaceuticals, Inc.

Cartesian Therapeutics, Inc.

Annovis Bio, Inc.

Dilution score: 48/100 (MEDIUM), 51.5 months cash

13F fund flow: neutral, ? institutional managers

3538 PubMed publications found for Turn  .

Deep learning reveals FLAD1-mediated mitochondrial metabolic reprogramming in hypoxic tumors.

Strengthening D-A Push-Pull Interactions in BODIPY to Enhance Near-Infrared Absorption and Photothermal Conversion for Low-Intensity Photothermal Antitumor Therapy.

PIN1 inhibits ferroptosis in gastric cancer cells by regulating the CPEB1‑GPX4 pathway.

[The effectiveness of Prostatex Plus in the treatment of patients with chronic abacterial prostatitis cate- gories III B].

AI-driven photophysics-aware design of fluorescent probes with applications in α-synuclein biosensing and inhibitor screening.

Short interest: 0.35% of float, squeeze risk: LOW

SW convergence: 50/100 (Neutral), 1 bullish / 0 bearish signals

<article class="bts-verified-summary" data-ticker="TTRX">
<p>Turn Therapeutics Inc. (TTRX) has no currently recruiting or active clinical trials where it is listed as lead sponsor on ClinicalTrials.gov.</p>
<p>TTRX has 5 Form 4 insider filings recorded at the SEC in the past 30 days<sup><a href="#fn-1">[1]</a></sup>.</p>
<section class="sources" data-nosnippet aria-label="Sources"><h3>Sources</h3><ol><li id="fn-1">SEC EDGAR · 0002023016 (2026-06-17) <a href="https://efts.sec.gov/LATEST/search-index?q=%22TTRX%22&amp;forms=4&amp;dateRange=custom&amp;startdt=2026-05-18&amp;enddt=2026-06-17" rel="nofollow noopener noreferrer">↗</a></li></ol></section>
</article>

SEC EDGAR — 0002023016

Turn Therapeutics Inc. (TTRX) — BioTechSigns Verified Summary

Turn Therapeutics Inc. (TTRX) has no currently recruiting or active clinical trials where it is listed as lead sponsor on ClinicalTrials.gov.

TTRX has 5 Form 4 insider filings recorded at the SEC in the past 30 days[1].

Sources:
[1] SEC EDGAR, 0002023016. Source last updated 2026-06-17, retrieved 2026-06-17.
    https://efts.sec.gov/LATEST/search-index?q=%22TTRX%22&forms=4&dateRange=custom&startdt=2026-05-18&enddt=2026-06-17